226 related articles for article (PubMed ID: 26679631)
1. CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.
Cutolo M; Sulli A; Paolino S; Pizzorni C
Expert Rev Clin Immunol; 2016; 12(4):417-25. PubMed ID: 26679631
[TBL] [Abstract][Full Text] [Related]
2. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis.
Cutolo M; Nadler SG
Autoimmun Rev; 2013 May; 12(7):758-67. PubMed ID: 23340277
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
Liu PC; Ssu CT; Tsao YP; Liou TL; Tsai CY; Chou CT; Chen MH; Leu CM
Arthritis Res Ther; 2020 Mar; 22(1):64. PubMed ID: 32228715
[TBL] [Abstract][Full Text] [Related]
4. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.
Bonelli M; Göschl L; Blüml S; Karonitsch T; Hirahara K; Ferner E; Steiner CW; Steiner G; Smolen JS; Scheinecker C
Rheumatology (Oxford); 2016 Apr; 55(4):710-20. PubMed ID: 26672908
[TBL] [Abstract][Full Text] [Related]
5. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept.
Laganà B; Vinciguerra M; D'Amelio R
Clin Drug Investig; 2009; 29(3):185-202. PubMed ID: 19243211
[TBL] [Abstract][Full Text] [Related]
6. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells.
Lorenzetti R; Janowska I; Smulski CR; Frede N; Henneberger N; Walter L; Schleyer MT; Hüppe JM; Staniek J; Salzer U; Venhoff A; Troilo A; Voll RE; Venhoff N; Thiel J; Rizzi M
J Autoimmun; 2019 Jul; 101():145-152. PubMed ID: 31054942
[TBL] [Abstract][Full Text] [Related]
7. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
8. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis.
Vierboom MP; Breedveld E; Kap YS; Mary C; Poirier N; 't Hart BA; Vanhove B
Clin Exp Immunol; 2016 Mar; 183(3):405-18. PubMed ID: 26540618
[TBL] [Abstract][Full Text] [Related]
10. Memory B Cells and Response to Abatacept in Rheumatoid Arthritis.
Gazeau P; Alegria GC; Devauchelle-Pensec V; Jamin C; Lemerle J; Bendaoud B; Brooks WH; Saraux A; Cornec D; Renaudineau Y
Clin Rev Allergy Immunol; 2017 Oct; 53(2):166-176. PubMed ID: 28477078
[TBL] [Abstract][Full Text] [Related]
11. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
[TBL] [Abstract][Full Text] [Related]
12. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
13. How does abatacept really work in rheumatoid arthritis?
Bonelli M; Scheinecker C
Curr Opin Rheumatol; 2018 May; 30(3):295-300. PubMed ID: 29401118
[TBL] [Abstract][Full Text] [Related]
14. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
15. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
Shergy WJ
Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting costimulatory activation of T cells : a viable treatment option for rheumatoid arthritis?
Pollard LC
Drugs; 2007; 67(1):1-9. PubMed ID: 17209660
[TBL] [Abstract][Full Text] [Related]
17. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.
Koenders MI; Marijnissen RJ; Joosten LA; Abdollahi-Roodsaz S; Di Padova FE; van de Loo FA; Dulos J; van den Berg WB; Boots AM
Arthritis Rheum; 2012 Jun; 64(6):1762-70. PubMed ID: 22213107
[TBL] [Abstract][Full Text] [Related]
18. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
[TBL] [Abstract][Full Text] [Related]
19. Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Malmström V; Trollmo C; Klareskog L
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S15-20. PubMed ID: 15833144
[TBL] [Abstract][Full Text] [Related]
20. [Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
Harigai M
Clin Calcium; 2007 Apr; 17(4):577-84. PubMed ID: 17404488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
